Fosun Pharma to invest $27.5 mil. in AriBio after AR1001 licensing deal Korea Biomedical Review 05:20 Fri, 03 Jul
AriBio completes main phase 3 dosing for oral Alzheimer's drug AR1001, topline data due this fall Korea Biomedical Review 05:49 Mon, 29 Jun